Premium
Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted
Author(s) -
Yasuda Takayuki,
Nitta Masayuki,
Komori Takashi,
Kobayashi Tatsuya,
Masui Kenta,
Maruyama Takashi,
Sawada Tatsuo,
Muragaki Yoshihiro,
Kawamata Takakazu
Publication year - 2018
Publication title -
neuropathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 61
eISSN - 1440-1789
pISSN - 0919-6544
DOI - 10.1111/neup.12406
Subject(s) - oligodendroglioma , procarbazine , gliosarcoma , temozolomide , medicine , radiation therapy , oligodendroglial tumor , glioma , idh1 , nuclear medicine , vincristine , lesion , chemotherapy , pathology , cancer research , radiology , mutant , astrocytoma , biology , biochemistry , gene , cyclophosphamide
Herein, we present a rare case of gliosarcoma arising from oligodendroglioma, isocitrate dehydrogenase ( IDH ) mutant and 1p/19q codeleted. A 36‐year‐old man presented with a non‐enhanced calcified abnormal lesion on the right frontal lobe. The patient underwent subtotal surgical resection, PAV chemotherapy (procarbazine, nimustine (ACNU) and vincristine), and fractionated radiotherapy with 50 Gy. The pathological diagnosis was oligodendroglioma, IDH mutant and 1p/19q codeleted, W orld H ealth O rganization 2016 grade II . Six years later, a new enhanced lesion appeared, and the recurrent tumor was surgically removed. Although the histopathological findings indicated gliosarcoma, the recurrent tumor still demonstrated the IDH mutation and 1p/19q codeleted. Thus, the recurrent tumor was considered to originate from oligodendroglioma, rather than being newly generated after chemoradiotherapy. Interestingly, the second recurrent tumor responded well to temozolomide chemotherapy. Based on the findings of this case, oligodendrogliomas have the potential for mesenchymal transformation on progression, while keeping their genotype.